Predict your next investment

Private Equity
hbmpartners.com

See what CB Insights has to offer

Investments

100

Portfolio Exits

36

Funds

1

About HBM Partners

HBM BioCapital (EUR) L.P. and HBM BioCapital (USD) L.P. are private equity funds with a total committed capital of EUR 115 million. The funds are managed by HBM Partners and are focused on healthcare / life science investments in Europe and the U.S. They were launched in 2005. HBM BioCapital I has made investments in 15 private companies in the pharma, biotechnology, medical devices and diagnostics industries, seven of which have been sold or listed on a stock exchange. Larger transactions were shared with HBM BioVentures. Investors in HBM BioCapital I are HBM BioVentures, larger institutional investors and pharma entrepreneurs.

HBM Partners Headquarter Location

PO-Box 1145

Zug, CH-6301,

Switzerland

+41 43 888 7171

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest HBM Partners News

Neuron23 Grabs $100M in Series C

Mar 30, 2022

Neuron23 Inc., an early stage biotechnology company focused on developing precision medicines for genetically defined neurological and immunological diseases, has closed a $100 million Series C financing round led by SoftBank Vision Fund 2, bringing the company's total financing raised to date to $213.5 million. Neuron23's Series A and B investors - Westlake Village BioPartners, Kleiner Perkins, Redmile Group, Cowen Healthcare Investments, Acorn Bioventures, HBM Partners, Perceptive Advisors, and Surveyor Capital (a Citadel company) - also participated in the Series C financing round. (c)2011-2020 by Massinvestor, Inc. For contact info, please check out our about page.

HBM Partners Investments

100 Investments

HBM Partners has made 100 investments. Their latest investment was in Neuron23 as part of their Series C on March 3, 2022.

CBI Logo

HBM Partners Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

3/30/2022

Series C

Neuron23

$100M

No

2

12/29/2021

Series G

Gynesonics

$32.5M

No

5/20/2021

Series C

Numab Therapeutics

$111M

Yes

6

3/8/2021

Series D

Subscribe to see more

$99M

Subscribe to see more

10

1/11/2021

Series E

Subscribe to see more

$99M

Subscribe to see more

10

Date

3/30/2022

12/29/2021

5/20/2021

3/8/2021

1/11/2021

Round

Series C

Series G

Series C

Series D

Series E

Company

Neuron23

Gynesonics

Numab Therapeutics

Subscribe to see more

Subscribe to see more

Amount

$100M

$32.5M

$111M

$99M

$99M

New?

No

No

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

2

6

10

10

HBM Partners Portfolio Exits

36 Portfolio Exits

HBM Partners has 36 portfolio exits. Their latest portfolio exit was Arena Pharmaceuticals on December 13, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

12/13/2021

Acq - P2P

$99M

5

6/29/2021

Acquired

$99M

2

7/24/2020

IPO

$99M

7

4/18/2019

IPO

Subscribe to see more

$99M

Subscribe to see more

10

9/21/2018

IPO

Subscribe to see more

$99M

Subscribe to see more

10

Date

12/13/2021

6/29/2021

7/24/2020

4/18/2019

9/21/2018

Exit

Acq - P2P

Acquired

IPO

IPO

IPO

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Sources

5

2

7

10

10

HBM Partners Fund History

1 Fund History

HBM Partners has 1 fund, including HBM Cobra India.

Closing Date

Fund

Fund Type

Status

Amount

Sources

3/5/2020

HBM Cobra India

$48.86M

1

Closing Date

3/5/2020

Fund

HBM Cobra India

Fund Type

Status

Amount

$48.86M

Sources

1

HBM Partners Team

3 Team Members

HBM Partners has 3 team members, including current Chief Executive Officer, Andreas Wicki.

Name

Work History

Title

Status

Andreas Wicki

Chief Executive Officer

Current

Erwin Troxler

Chief Financial Officer

Current

Ulrich Geilinger

Senior Partner

Current

Name

Andreas Wicki

Erwin Troxler

Ulrich Geilinger

Work History

Title

Chief Executive Officer

Chief Financial Officer

Senior Partner

Status

Current

Current

Current

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.